Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wells Fargo Releases a Hold Rating on Pfizer (PFE)

Tipranks - Tipranks - Tue Apr 14, 6:02AM CDT

In a report released today, Mohit Bansal from Wells Fargo assigned a Hold rating to Pfizer, with a price target of $28.00.

Claim 30% Off TipRanks

According to TipRanks, Bansal is a 5-star analyst with an average return of 9.2% and a 55.65% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Pfizer.

In addition to Wells Fargo, Pfizer also received a Hold from J.P. Morgan’s Chris Schott in a report issued on April 10. However, on April 7, RBC Capital maintained a Sell rating on Pfizer (NYSE: PFE).

See today’s best-performing stocks on TipRanks >>

Based on Pfizer’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $17.56 billion and a GAAP net loss of $1.65 billion. In comparison, last year the company earned a revenue of $17.76 billion and had a net profit of $403 million

Read More on PFE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).